Is NCT05315700 recruiting in Long Beach, CA?

Yes, NCT05315700 is currently recruiting participants at its Long Beach, CA location. This advanced solid tumors clinical trial is actively enrolling qualified participants.

How do I join the advanced solid tumors clinical trial in Long Beach?

To join this clinical trial in Long Beach, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Long Beach clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Advanced Solid Tumors Clinical Trial in Long Beach, CA

About This Advanced Solid Tumors Study in Long Beach

The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.

Sponsor: ORIC Pharmaceuticals

Who Can Participate

Inclusion Criteria

Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented EGFR or HER2 exon 20 insertion mutation or atypical EGFR mutation as determined by any nucleic acid-based diagnostic testing method, or HER2 amplification/overexpression as determined by an immunohistochemistry (IHC) or an in situ hybridization (ISH) test

Part I Dose Escalation (CLOSED) Any solid tumor with

EGFR exon 20 insertion mutation

HER2 exon 20 insertion mutation

Atypical EGFR mutations (NSCLC only) (Appendix 8)

HER2 amplification or overexpression (HER2+)

Previously received and progressed on or after available standard therapies and for whom additional standard therapy is considered unsuitable or intolerable

Part I Extension (ONGOING)

Cohort IA: Patients with HER2+ breast cancer previously received and progressed on or after available standard therapies and for whom additional standard therapy is considered unsuitable or intolerable

Cohort IB: NSCLC patients with EGFR exon 20 insertion mutation previously treated with chemotherapy and amivantamab

Cohort IC: Treatment-naïve NSCLC patients with EGFR exon 20 insertion mutation

Cohort ID: Treatment-naïve NSCLC patients with EGFR atypical mutations

Part II Dose Optimization (ONGOING): NSCLC patients with

Cohort IIA: EGFR exon 20 insertion mutation, patients must have received platinum-based chemotherapy or other chemotherapy regimen if platinum- based chemotherapy was contraindicated. Additionally, patients must be naïve to an EGFR exon 20 targeted agent, ie, must have declined or be ineligible for all available exon 20 targeted therapies with proven benefit

Cohort IIB: HER2 exon 20 insertion mutation, patients must have received platinum-based chemotherapy or other chemotherapy regimen if platinum- based chemotherapy was contraindicated. Additionally, patients must be naïve to a HER2 exon 20 targeted TKI

Cohort IIC: Atypical EGFR mutation, patients may have received a prior EGFR TKI

Agreement and ability to undergo pretreatment biopsy

Measurable disease according to RECIST 1.1

CNS involvement, which is either previously treated and controlled, or untreated and asymptomatic

ECOG performance status of 0 or 1

Adequate organ function

Exclusion Criteria

Known EGFR T790M mutation

Leptomeningeal disease and spinal cord compression \-- Except if LMD has been reported radiographically on baseline MRI, but is not suspected clinically by the Investigator; the subject must be free of neurological symptoms of LMD

History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months

Past medical history of interstitial lung disease (ILD), drug induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD

Known, symptomatic human immunodeficiency virus (HIV) infection

Known active infection requiring treatment or history of hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients positive for HBsAg but normal HBV DNA level are allowed.

Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes

Any other concurrent serious uncontrolled medical, psychological, or addictive conditions

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Long Beach?

Yes, this clinical trial (NCT05315700) has an active research site in Long Beach, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Advanced Solid Tumors Treatment Options in Long Beach, CA

If you're searching for advanced solid tumors treatment options in Long Beach, CA, this clinical trial (NCT05315700) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Long Beach research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all advanced solid tumors clinical trials near you to find additional studies recruiting in your area.

Advanced Solid Tumors Clinical Trial in Long Beach, CA

Expert Care in Long Beach

IRB Approved

No-Cost Care

Apply for This Long Beach Location

Why Participate?

Simple Process